Laura Layos

1.9k total citations
30 papers, 973 citations indexed

About

Laura Layos is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Laura Layos has authored 30 papers receiving a total of 973 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in Laura Layos's work include Colorectal Cancer Treatments and Studies (16 papers), Cancer Treatment and Pharmacology (6 papers) and Curcumin's Biomedical Applications (4 papers). Laura Layos is often cited by papers focused on Colorectal Cancer Treatments and Studies (16 papers), Cancer Treatment and Pharmacology (6 papers) and Curcumin's Biomedical Applications (4 papers). Laura Layos collaborates with scholars based in Spain, United Kingdom and United States. Laura Layos's co-authors include Eva Martinez‐Balibrea, José Luís Zamora Manzano, Anna Martínez‐Cardús, Cristina Bugés, Vicenç Ruiz de Porras, Albert Abad, Sara Bystrup, Alba Ginés, Laia Vilà and María de los Llanos Gil and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Laura Layos

30 papers receiving 962 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laura Layos Spain 13 564 485 211 115 104 30 973
Vicenç Ruiz de Porras Spain 13 257 0.5× 374 0.8× 191 0.9× 119 1.0× 64 0.6× 32 720
Cristina Bugés Spain 9 354 0.6× 387 0.8× 153 0.7× 113 1.0× 87 0.8× 21 693
Denise K. Oelschlager United States 20 325 0.6× 602 1.2× 197 0.9× 258 2.2× 83 0.8× 41 1.2k
Rishil J. Kathawala United States 22 1.2k 2.1× 904 1.9× 183 0.9× 116 1.0× 119 1.1× 31 1.7k
Eva Martinez‐Balibrea Spain 20 898 1.6× 937 1.9× 399 1.9× 209 1.8× 237 2.3× 43 1.7k
Jian Suo China 17 257 0.5× 491 1.0× 228 1.1× 129 1.1× 139 1.3× 29 906
Alex Starr Israel 16 350 0.6× 532 1.1× 111 0.5× 100 0.9× 50 0.5× 25 936
Teng Yu China 18 177 0.3× 496 1.0× 139 0.7× 99 0.9× 132 1.3× 47 906
Liuxing Wang China 18 210 0.4× 629 1.3× 402 1.9× 104 0.9× 49 0.5× 47 905

Countries citing papers authored by Laura Layos

Since Specialization
Citations

This map shows the geographic impact of Laura Layos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Layos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Layos more than expected).

Fields of papers citing papers by Laura Layos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Layos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Layos. The network helps show where Laura Layos may publish in the future.

Co-authorship network of co-authors of Laura Layos

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Layos. A scholar is included among the top collaborators of Laura Layos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Layos. Laura Layos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Carrato, Alfredo, Roberto Pazo-Cid, Teresa Macarulla, et al.. (2024). Nab -Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer. NEJM Evidence. 3(2). 7 indexed citations
2.
Pous, Anna, et al.. (2023). HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies. International Journal of Molecular Sciences. 24(14). 11403–11403. 21 indexed citations
3.
Abad, Albert, et al.. (2023). Liquid biopsy, big data and artificial intelligence as a new global clinical trial model in targeted therapy. SHILAP Revista de lepidopterología. 1. 100008–100008. 1 indexed citations
4.
Sun, Chen, et al.. (2022). Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going. Clinical Colorectal Cancer. 21(2). 71–79. 4 indexed citations
5.
6.
Vila, Mireia Margelí, Eudald Felip, Laura Layos, et al.. (2021). Abstract LB112: SAMHD1: A new Prognostic Marker in Breast Cancer (BC). Cancer Research. 81(13_Supplement). LB112–LB112. 1 indexed citations
7.
Hierro, Cinta, J.P. Suárez Fernández, Cristina Bugés, et al.. (2020). Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents. Drugs in Context. 9. 1–13. 5 indexed citations
8.
Porras, Vicenç Ruiz de, Laura Layos, & Eva Martinez‐Balibrea. (2020). Curcumin: A therapeutic strategy for colorectal cancer?. Seminars in Cancer Biology. 73. 321–330. 39 indexed citations
9.
10.
Fernández-Martos, Carlos, Carles Pericay, Ferrán Losa, et al.. (2019). Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma. JAMA Oncology. 5(11). 1566–1566. 36 indexed citations
11.
Porras, Vicenç Ruiz de, Sara Bystrup, Eva Musulén, et al.. (2019). Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients. Cancers. 11(10). 1540–1540. 19 indexed citations
12.
Font, Rebeca, Josep Alfons Espinàs, Laura Layos, et al.. (2017). Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: do we need to worry?. Annals of Oncology. 28(4). 831–835. 16 indexed citations
13.
Manzano, José Luís Zamora, Laura Layos, Cristina Bugés, et al.. (2016). Resistant mechanisms to BRAF inhibitors in melanoma. Annals of Translational Medicine. 4(12). 237–237. 177 indexed citations
14.
Porras, Vicenç Ruiz de, Sara Bystrup, Anna Martínez‐Cardús, et al.. (2016). Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway. Scientific Reports. 6(1). 24675–24675. 113 indexed citations
15.
Martinez‐Balibrea, Eva, Anna Martínez‐Cardús, Alba Ginés, et al.. (2015). Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance. Molecular Cancer Therapeutics. 14(8). 1767–1776. 261 indexed citations
16.
Ginés, Alba, Sara Bystrup, Vicenç Ruiz de Porras, et al.. (2015). PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines. PLoS ONE. 10(5). e0123830–e0123830. 32 indexed citations
17.
18.
Grande, Enrique, Carmen Guillén‐Ponce, Margarita Reboredo, et al.. (2014). Regorafenib as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC): A study of the Spanish Cooperative Group for digestive tumor therapy (TTD).. Journal of Clinical Oncology. 32(15_suppl). TPS3651–TPS3651. 3 indexed citations
19.
Abad, Albert, B. Massuti Sureda, Cristina Grávalos, et al.. (2014). Ras Analysis of the Planet Study: Phase Ii Trial of Panitumumab (P) Plus Folfox4 or Folfiri in Subjects with Wild-Type (Wt) Kras Colorectal Cancer (Crc) and Liver-Limited Disease (Lld). Annals of Oncology. 25. iv189–iv189. 1 indexed citations
20.
Martinez‐Balibrea, Eva, Albert Abad, Anna Martínez‐Cardús, et al.. (2010). UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. British Journal of Cancer. 103(4). 581–589. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vicenç Ruiz de Porras Breakdown of academic impact, for papers by Cristina Bugés Breakdown of academic impact, for papers by Denise K. Oelschlager Breakdown of academic impact, for papers by Rishil J. Kathawala Breakdown of academic impact, for papers by Eva Martinez‐Balibrea Breakdown of academic impact, for papers by Jian Suo Breakdown of academic impact, for papers by Alex Starr Breakdown of academic impact, for papers by Teng Yu Breakdown of academic impact, for papers by Liuxing Wang
Rankless by CCL
2026